TL/DR –
Johnson & Johnson (J&J) has maintained its growth projections in spite of impending pressure from potential government price negotiations. As the US government negotiates with the industry over pricing, J&J is bracing for a hit on its net drug prices, expecting a drop between 4% and 6% in 2022. Even with the potential price drop, the company is still predicting sales growth of 42% through 2025.
Understanding the Impact of IRA Price Negotiations on J&J’s Growth Projections
Amid upcoming IRA price negotiations, J&J is maintaining its growth projections. The pharmaceutical giant is preparing for potential impacts while ensuring its growth projections remain stable.
—
Read More US Economic News